Results 31 to 40 of about 5,449 (190)
In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany
Journal of Global Antimicrobial Resistance, 2022 : Objectives: Widespread antimicrobial resistance in Gram-negative bacteria (GNB), particularly carbapenem resistance, represents a major clinical challenge.
Philipp Thelen +5 more
doaj +1 more source
Microbiology Spectrum, 2022 Cefiderocol has been approved in the United States and Europe but not in China. We aim to evaluate carbapenem-resistant Enterobacterales (CRE) susceptibility to cefiderocol to provide baseline data and investigate the resistance mechanism.
Qi Wang +16 more
doaj +1 more source
Mechanism of action of cefiderocol
Revista Española de Quimioterapia, 2022 Gram-negative bacilli are intrinsically resistant to many antibiotics due to the low permeability of their outer membrane. The most effective strategy to solve this problem has been the design of antibiotics that cross the membrane using specific transport systems.
Soriano, Alex, Mensa, Josep
openaire +2 more sources
Therapeutic Advances in Urology, 2022 Cefiderocol is a unique siderophore cephalosporin antimicrobial agent that has shown promise in treating complicated urinary tract infections (cUTI). Urinary tract infections are commonly diagnosed infections with risk increasing with age and prevalence ...
Hongmei Wang, Brittany N. Palasik
doaj +1 more source
The solution to drug resistance of Gram-negative bacteria – Cefiderocol [PDF]
, 2023 Introduction: A major public health problem is the emergence of anti-gram-negative antimicrobial resistance worldwide. Cefiderocol is a new agent targeting Gram-negative bacteria, including strains with resistance to carbapenems.
Jastrzębska, Ilona +4 more
core +3 more sources
Microbiology Spectrum, 2023 In this study, we aimed to comparatively evaluate the in vitro activity of cefiderocol versus other antimicrobials against a well-characterized collection of metallo-beta-lactamase (MBL)-producing Gram-negative bacilli (MBL-GNB) isolates from hospitals ...
M. Delgado-Valverde +4 more
doaj +1 more source
Probable Tigecycline-Induced Acute Eosinophilic Pneumonia: A Case Report. [PDF]
Respirol Case RepA 25‐year‐old man developed acute hypoxaemic respiratory failure after 21 days of tigecycline therapy for osteomyelitis caused by multidrug‐resistant organisms. Although the clinical response followed multiple simultaneous interventions and therefore does not establish causality, the overall findings support tigecycline as the probable causative agent.
Eom A, Kioka M.
europepmc +2 more sources
Journal of Global Antimicrobial Resistance, 2021 : Objectives: The incidence of antimicrobial resistance in Europe is rising. Cefiderocol is approved in Europe for treatment of aerobic Gram-negative bacterial (GNB) infections in adults with limited treatment options. We report the in vitro activity of
Emilia Cercenado +5 more
doaj +1 more source
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
, 2021 Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of ...
Yahiya Y. Syed (6594444)
core +1 more source
Journal of Global Antimicrobial Resistance, 2021 Objectives: The aim of this study was to investigate the clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections. Methods: The PubMed, Embase and Cochrane Library databases as well as the clinical trials registries of ...
Shun-Chung Hsueh +4 more
doaj +1 more source